Valbiotis SA (ALVAL.PA)
- Previous Close
3.9650 - Open
3.9200 - Bid --
- Ask --
- Day's Range
3.9000 - 3.9750 - 52 Week Range
2.9000 - 7.5000 - Volume
42,504 - Avg. Volume
30,410 - Market Cap (intraday)
61.531M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8500 - Earnings Date Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.10
Valbiotis SA engages in the research and development of health nutrition products to prevent and control metabolic and cardiovascular diseases in France. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II/III clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with MASLD. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
www.valbiotis.comRecent News: ALVAL.PA
Performance Overview: ALVAL.PA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALVAL.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALVAL.PA
Valuation Measures
Market Cap
61.53M
Enterprise Value
54.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.02
Price/Book (mrq)
5.27
Enterprise Value/Revenue
12.42
Enterprise Value/EBITDA
-6.53
Financial Highlights
Profitability and Income Statement
Profit Margin
-108.21%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
6.81M
Net Income Avi to Common (ttm)
-7.37M
Diluted EPS (ttm)
-0.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Research Analysis: ALVAL.PA
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: ALVAL.PA
ALVAL.PA does not have Company Insights